AG1 Subsequent Gen is a dietary powder containing an upgraded methylated B advanced, added nutritional vitamins and minerals and 5 clinically-studied probiotic strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus plantarum.
The launch is backed by 4 randomized, placebo-controlled medical trials which exhibit the product’s means to extend key nutrient ranges and enhance intestine well being.
“Investing in medical trials is necessary as a result of prospects deserve extra readability across the high quality, efficacy and claims of the dietary supplements they select,” Cole advised NutraIngredients. “We’re proud to be setting the bar for high quality and scientific rigor even larger, because it’s the proper subsequent chapter for the complement business.”
Clinically studied substances
Previously generally known as Athletic Greens, AG1 was based in 2010. Since then, the corporate’s flagship product AG1 has been reformulated a number of occasions as a way to align with the newest scientific proof and analysis.
Now, the day by day greens powder comprises greater than 75 substances together with nutritional vitamins, minerals, herbs, antioxidants, superfoods, mushrooms, adaptogens and pre- and probiotics.
Designed to supply a extra complete strategy to well being, AG1 Subsequent Gen is supported by soon-to-be-published information from new medical trials demonstrating its means to extend ranges of gut-friendly micro organism and shut frequent nutrient gaps. AG1 previewed findings indicating that the method elevates key nutrient ranges (together with folate and vitamin C) inside three months and will increase wholesome intestine micro organism tenfold.
Revealed analysis utilizing the earlier method has demonstrated related outcomes, with one double-blind, randomized, placebo-controlled trial displaying that supplementation with AG1’s day by day powder more than doubled ranges of micro organism corresponding to B. bifidum and L. acidophilus in wholesome adults in comparison with placebo.
As well as, an in vitro trial confirmed that the complement had measurable results on the intestine microbiome in comparison with a multivitamin pill and was in a position to ship more absorbable nutrients, suggesting improved bioavailability.
The brand new analysis goals to bolster the scientific rigor behind AG1’s new powdered product, which has maintained its NSF Licensed for Sport certification.
The place subsequent?
Wanting forward, Cole mentioned AG1 is dedicated to conducting extra peer-reviewed, unbiased analysis on the whole method of all future merchandise.
With plans to speculate greater than $20 million (€17.6 million) over the subsequent three years, the corporate additionally hopes to accomplice with main universities centered on advancing vitamin science and broaden its in-house group of researchers, clinicians and scientists.
“We’re in an thrilling interval of innovation on the model,” Cole mentioned. “We’ll proceed to put money into analysis and lead and elevate the complement class. We’re additionally increasing channels to satisfy extra prospects and can innovate merchandise to serve quite a lot of want states—delivering on our mission of empowering well being.”
